Comparing the current results to its competitors, Kuvatris Therapeutics Inc reported Revenue decrease in the 3 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 14.2 %, recorded in the same quarter.
Kuvatris Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 1410.55 %
Kuvatris Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical industry, facing competition from commercial pharmaceutical and biotechnology companies, academic institutions, government agencies, and research organizations. Competitors often have greater resources and more advanced product candidates. In the development of PAX-101 for treating autism spectrum disorder (ASD), there is currently no FDA-approved medication for core symptoms, but several companies are developing competing drugs. Notable competitors in ASD include CureMark LLC, which is conducting Phase 3 studies for CM-AT; Yamo Pharmaceuticals, with Phase 2 studies for LI-79; and GW Pharmaceuticals, conducting Phase 2 studies for Cannabidivarin.
Publicly Traded Peers of Kuvatris Therapeutics Inc
Trevi Therapeutics Inc Share Performance
+39.61%
This Year
Trevi Therapeutics Inc
Profile
Trevi Therapeutics Inc is a biopharmaceutical company that specializes in developing therapies for neurologically mediated conditions. Their business model focuses on identifying and developing innovative treatment options that target specific receptors in the nervous system. By leveraging their expertise in neuroscience and drug development, Trevi aims to bring novel therapies to market and improve the lives of patients suffering from these conditions.
Syndax Pharmaceuticals Inc has a business model centered around developing innovative cancer treatments. They focus on leveraging their expertise in epigenetics and immuno-oncology to create therapies that target specific cancer types. Syndax collaborates with strategic partners and utilizes clinical trials to bring their treatments to market and improve patient outcomes.
Sellas Life Sciences Group Inc is a biopharmaceutical company that focuses on developing and commercializing immunotherapeutic products for various cancer indications, utilizing innovative technologies. The company aims to meet the need for more effective treatment options by leveraging its expertise in immuno-oncology and precision medicine.
Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company that operates on a business-to-business (B2B) model. They develop and manufacture a wide range of pharmaceutical products and then distribute them to other companies or medical institutions for further distribution or use. Their primary focus is on ensuring the quality and effectiveness of their products while partnering with other entities to ensure their widespread availability in the market.
Sagimet Biosciences Inc is a biopharmaceutical company that operates on a research-based business model focused on developing therapeutic solutions for metabolic diseases. They employ a multidisciplinary approach that combines scientific research, preclinical assessments, and clinical trials to advance their drug candidates. Sagimet Biosciences aims to bring effective treatments to patients by leveraging their expertise in metabolic disease biology and collaborating with key stakeholders in the medical community.
Sources:
Kuvatris Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kuvatris Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
